Premium exit.
A four-year technology transformation in a PE-backed pharmaceutical cold chain business operating across 26 countries, recognised as one of Europe's fastest-growing companies. The technology went through buy-side due diligence as an asset, with me as the sole technology counterpart to the auditors.
Premium exit. Retained by the buyer.
